Concord Wealth Partners Astrazeneca PLC Transaction History
Concord Wealth Partners
- $710 Million
- Q3 2025
A detailed history of Concord Wealth Partners transactions in Astrazeneca PLC stock. As of the latest transaction made, Concord Wealth Partners holds 671 shares of AZN stock, worth $59,987. This represents 0.01% of its overall portfolio holdings.
Number of Shares
671
Previous 671
-0.0%
Holding current value
$59,987
Previous $46,000
10.87%
% of portfolio
0.01%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding AZN
# of Institutions
1,498Shares Held
500MCall Options Held
5.59MPut Options Held
3.18M-
Price T Rowe Associates Inc Baltimore, MD49.1MShares$4.39 Billion0.4% of portfolio
-
Primecap Management CO Pasadena, CA39.9MShares$3.56 Billion2.42% of portfolio
-
Bank Of America Corp Charlotte, NC32.6MShares$2.92 Billion0.18% of portfolio
-
Wellington Management Group LLP Boston, MA32.3MShares$2.89 Billion0.45% of portfolio
-
Capital International Investors Los Angeles, CA25.1MShares$2.24 Billion0.33% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $277B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...